Skip to main content

Advertisement

Table 3 Cost-effectiveness and threshold gel prices under variations to introduction scenario assumptions and sensitivity analysis [2012 USD]

From: Cost-effectiveness of tenofovir gel in urban South Africa: model projections of HIV impact and threshold product prices

Variations to introduction scenario       
  Reduction in condom use Coverage Consistency of gel use HIV efficacy $/DALY averted % change Threshold price % change
Baseline 0% 30% 72% 54% $297   $0.12  
  5% 30% 72% 54% $586 97% $0.03 -74%
  10% 30% 72% 54% $1,219 310% cannot be achieved  
  0% 60% 72% 54% $285 -4% $0.13 5%
  0% 60% 50% 54% $468 58% $0.03 -78%
  0% 30% 72% 83% -$14 -105% $0.33 166%
Cost sensitivity analysis        
1 dose per sex-act     $78 -74% $0.25 100%
Discount rate 0%      -$243 -182% $0.43 244%
Discount rate 6%      $525 77% cannot be achieved  
ART costs 10% lower     $344 16% $0.10 -21%
ART costs 25% lower     $413 39% $0.06 -53%
All other input costs 25% higher     $402 35% $0.06 -48%
All other input costs 25% lower     $193 -35% $0.18 48%
Input +25%, ART-10%     $448 51% $0.04 -69%
Input +25%, ART-25%     $518 74% -$0.00 -100%
ART coverage 80%     $163 -45% $0.24 90%